TABLE 3.
Genetic scores and prediction of liver‐related outcomes.
| Reference | Score | Outcome | AUROC | Sensitivity | Specificity |
|---|---|---|---|---|---|
| Donati et al. | HCC risk score: Age, sex, obesity, T2DM, severe fibrosi, number of risk alleles (PNPLA3 I148M, TM6SF2 E167K, and MBOAT7 rs641738 C > T risk variants | Prediction of HCC | 0.96 ± 0.04 | 96% | 89% |
| Bianco et al. | PRS‐HFC: PNPLA3, TM6SF2, MBOAT7 and GCKR risk alleles | Prediction of HCC | 0.64 | 43% | 80% |
| PRS‐5: PRS adjusted for the rs72613567 HSD17B13 variant | Prediction of HCC | 0.65 | 43% | 79% | |
| Pennisi et al. | GEMS score: Sex, age, diabetes, HDL, albumin, PLT and PNPLA3, TM6SF2, HSD17B13 genotype | Prediction of liver‐related events | 0.87 | Not available | Not available |
| De vincentis et al. | Clinical scores (NFS, FIB4, APRI, BARD Forns) + PRS‐HFC | Prediction of severe liver disease (SLD) in overall population | 0.683, 0.670, 0.648, 0.603, 0.735 for NFS, FIB‐4, APRI, BARD and Forns respectively | Not available | Not available |
| Clinical scores (NFS, FIB4, APRI, BARD Forns) + PRS‐HFC | Prediction of SLD in subgroup with diabetes | 0.722, 0.753, 0.742, 0.669, 0.791 for NFS, FIB‐4, APRI, BARD and Forns respectively | Not available | Not available | |
| Clinical scores (NFS, FIB4, APRI, BARD Forns) + PRS‐HFC | Prediction of SLD in subgroup with obesity | 0.721, 0.723, 0.683, 0.671, 0.771 for NFS, FIB‐4, APRI, BARD and Forns respectively | Not available | Not available | |
| Clinical scores (NFS, FIB4, APRI, BARD Forns) + PRS‐HFC | Prediction of SLD in subgroup with FLI ≥60 | 0.700, 0.717, 0.684, 0.655, 0.754 for NFS, FIB‐4, APRI, BARD and Forns respectively | Not available | Not available |
Abbreviations: AUROC, area under the receiver‐operating characteristic curve; FLI, fatty liver index; GCKR, glucokinase regulator; HDL, high‐density lipoprotein; NFS, NAFLD fibrosis score.